Research progress on the role and mechanisms of action of sodium-dependent glucose transporter 2 inhibitors in heart failure with preserved ejection fraction
10.3760/cma.j.issn.0254-9026.2023.01.022
- VernacularTitle:钠-葡萄糖协同转运蛋白-2抑制剂在射血分数保留的心力衰竭中的作用及机制研究进展
- Author:
Zhulan CAI
1
;
Lingyun ZU
Author Information
1. 北京大学第三医院心内科、血管医学研究所；国家卫生健康委心血管分子生物学与调节肽重点实验室；分子心血管学教育部重点实验室；心血管受体研究北京市重点实验室，北京 100191
- Keywords:
Stroke volume;
Heart failure;
Sodium-dependent glucose transporter 2 inhibitor
- From:
Chinese Journal of Geriatrics
2023;42(1):113-118
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)are a new class of glucose-lowering drugs, can reduce blood sugar by inhibiting the reabsorption of glucose at the proximal tubule and are widely used in clinical treatment of type 2 diabetes.SGLT2i can not only lower blood sugar, but also offer multiple cardiovascular benefits.Several large randomized controlled trials have confirmed the safety and efficacy of SGLT2i for heart failure with preserved ejection fraction(HFpEF). Herein, we present an overview on advances in SGLT2i for HFpEF.
